Treatment of two patients with Herlitz junctional epidermolysis bullosa with artificial skin bioequivalents

Qiu Jie Jiang, Jan Izakovic, Martin Zenker, Manige Fartasch, Guerrino Meneguzzi, Wolfgang Rascher, Holm Schneider

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Objective: To evaluate the effects of a treatment with artificial skin bioequivalents in Herlitz junctional epidermolysis bullosa (H-JEB). Methods: Two infants, both homozygous for the Herlitz mutation R635X in the LAMB3 gene, who had refractory anemia and hypoproteinemia as a result of a continuous loss of body fluids through multiple large erosions, were treated with artificial skin bioequivalents. Results: In the first patient, 10 of 13 acute or chronic wounds were found healed 3 to 6 weeks after the treatment, and the protein, iron, and hemoglobin levels normalized. Normal weight gain and marked improvement of the quality of life for this patient's family have been evident since. Nine treated wounds remained healed for at least 18 weeks and appeared to be more resistant to trauma. In a skin biopsy from a treated site obtained after 9 weeks, DNA of the graft was still detectable by polymerase chain reaction. In the second patient, who was treated at a late stage of the disease, only 2 of 18 chronic wounds were found healed at 3 weeks after the treatment. One site remained healed completely, and some additional islets of the grafts persisted for longer. There were no adverse events. Conclusion: Early treatment with artificial skin substitutes may improve the clinical course of H-JEB. However, a true cure of the cutaneous manifestations of H-JEB would require gene therapy of autologous epidermal stem cells, which could then be transplanted by using this or a similar cultured skin bioequivalent.

Original languageEnglish (US)
Pages (from-to)553-559
Number of pages7
JournalJournal of Pediatrics
Issue number4
StatePublished - Oct 1 2002

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Treatment of two patients with Herlitz junctional epidermolysis bullosa with artificial skin bioequivalents'. Together they form a unique fingerprint.

Cite this